Intended for healthcare professionals


Half of trials supporting new cancer drug approval in Europe had high risk of bias

BMJ 2019; 366 doi: (Published 19 September 2019) Cite this as: BMJ 2019;366:l5619

Linked Research

Design characteristics, risk of bias, and reporting of RCTs supporting approvals of cancer drugs by EMA